 Daily Mail |
GSK buoyed by hopes of defending asthma drug
Financial Times GSK jumped 2.8 per cent to £12.62 on hopes it will be able to defend Advair, its blockbuster asthma franchise, from competition … FTSE 100 ends busy week on a positive note, despite opening dip on Wall Street Glaxo breathes easier as threat to Advair recedes |
View full post on asthma – Google News